{
    "ticker": "VERA",
    "name": "Veracyte, Inc.",
    "description": "Veracyte, Inc. is a pioneering genomic diagnostics company that focuses on enhancing patient care through the development of innovative diagnostic tests that improve the accuracy of disease diagnosis and treatment. Founded in 2013 and headquartered in South San Francisco, California, Veracyte specializes in providing solutions for patients with complex diseases, particularly in the fields of oncology and pulmonary medicine. The company is best known for its proprietary tests that leverage advanced genomic technologies to provide clear, actionable insights from tissue and cytology samples, thereby reducing the need for invasive procedures. Veracyte's flagship product, the Afirma Test, is widely recognized for its role in evaluating thyroid nodules, significantly helping to reduce unnecessary surgeries. In addition to thyroid testing, Veracyte has expanded its portfolio to include tests for lung cancer and other malignancies, firmly establishing itself as a leader in the diagnostics sector. With a commitment to improving patient outcomes and reducing healthcare costs, Veracyte continues to innovate and expand its test offerings while collaborating with healthcare providers to enhance the standard of care in cancer diagnostics.",
    "industry": [
        "Healthcare",
        "Diagnostics"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2013",
    "website": "https://www.veracyte.com",
    "ceo": "Bonnie Anderson",
    "social_media": {
        "twitter": "https://twitter.com/Veracyte",
        "linkedin": "https://www.linkedin.com/company/veracyte/"
    },
    "investor_relations": "https://investors.veracyte.com",
    "key_executives": [
        {
            "name": "Bonnie Anderson",
            "position": "CEO"
        },
        {
            "name": "Michael Nall",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Genomic Tests",
            "products": [
                "Afirma Test",
                "Percepta Test",
                "Envisia Test"
            ]
        }
    ],
    "seo": {
        "meta_title": "Veracyte, Inc. | Genomic Diagnostics and Innovative Testing Solutions",
        "meta_description": "Explore Veracyte, Inc., a leader in genomic diagnostics focused on improving patient care with innovative tests for cancer and thyroid conditions.",
        "keywords": [
            "Veracyte",
            "Genomic Diagnostics",
            "Cancer Testing",
            "Thyroid Diagnostics",
            "Afirma Test",
            "Percepta Test"
        ]
    },
    "faq": [
        {
            "question": "What is Veracyte known for?",
            "answer": "Veracyte is known for its genomic tests that improve the accuracy of disease diagnosis, particularly in oncology and thyroid conditions."
        },
        {
            "question": "Who is the CEO of Veracyte?",
            "answer": "Bonnie Anderson is the CEO of Veracyte, Inc."
        },
        {
            "question": "Where is Veracyte headquartered?",
            "answer": "Veracyte is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are Veracyte's main products?",
            "answer": "Veracyte's main products include the Afirma Test, Percepta Test, and Envisia Test."
        },
        {
            "question": "When was Veracyte founded?",
            "answer": "Veracyte was founded in 2013."
        }
    ],
    "competitors": [
        "EXAS",
        "NTRB",
        "MDXG"
    ],
    "related_stocks": [
        "ILMN",
        "CGTX",
        "GHDX",
        "MYGN"
    ]
}